BENITEC BIOPHARMA (BNTC) Posts $45.5M Annual Loss, Eyes Pivotal BB-301 Trial in 2027
The gene therapy developer closed fiscal 2026 with $180 million in cash, a fully enrolled high-dose cohort and FDA talks on a pivotal study design.
Benitec Biopharma (BNTC) reported results for the fiscal year ended June 30, 2026, posting a net loss attributable to shareholders of $45.5 million, or $0.98 per basic and diluted share, against a loss of $37.9 million, or $1.05 per share, a year earlier. The Hayward, California company also said all six patients in the low-dose cohort of its BB-301 gene therapy have completed 12 months of follow-up and that the high-dose cohort is fully enrolled, with a pivotal trial planned for mid-2027.
